Lexicon Pharmaceuticals (LXRX) Projected to Announce Earnings on Thursday

Lexicon Pharmaceuticals (NASDAQ:LXRX) is projected to issue its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect Lexicon Pharmaceuticals to announce earnings of ($0.0502) per share and revenue of $3.99 million for the quarter. Individuals may visit the the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, August 6, 2026 at 8:30 AM ET.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.00) EPS for the quarter, beating the consensus estimate of ($0.04) by $0.04. The firm had revenue of $21.10 million during the quarter, compared to the consensus estimate of $9.79 million. Lexicon Pharmaceuticals had a negative return on equity of 18.64% and a negative net margin of 37.46%. On average, analysts expect Lexicon Pharmaceuticals to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Lexicon Pharmaceuticals Stock Performance

NASDAQ:LXRX opened at $2.33 on Tuesday. The stock has a market cap of $1.03 billion, a P/E ratio of -33.28 and a beta of 1.08. The company has a current ratio of 18.80, a quick ratio of 18.77 and a debt-to-equity ratio of 0.24. The stock’s 50-day moving average is $2.18 and its 200-day moving average is $1.83. Lexicon Pharmaceuticals has a 1-year low of $1.02 and a 1-year high of $2.68.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on LXRX shares. Citigroup raised their price objective on shares of Lexicon Pharmaceuticals from $2.30 to $3.10 and gave the company a “buy” rating in a report on Monday, May 11th. Zacks Research raised shares of Lexicon Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Friday, July 3rd. Finally, Weiss Ratings upgraded shares of Lexicon Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, July 23rd. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $4.55.

Hedge Funds Weigh In On Lexicon Pharmaceuticals

A number of hedge funds have recently made changes to their positions in the stock. Hudson Bay Capital Management LP acquired a new position in shares of Lexicon Pharmaceuticals in the 2nd quarter worth approximately $26,000. Security National Bank of Sioux City Iowa IA acquired a new stake in shares of Lexicon Pharmaceuticals during the fourth quarter worth $31,000. EntryPoint Capital LLC acquired a new stake in shares of Lexicon Pharmaceuticals during the fourth quarter worth $39,000. Virtu Financial LLC bought a new position in Lexicon Pharmaceuticals during the fourth quarter worth $42,000. Finally, CIBC Asset Management Inc bought a new position in Lexicon Pharmaceuticals during the fourth quarter worth $45,000. 74.70% of the stock is currently owned by institutional investors.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company focused on the discovery and development of novel medicines through its proprietary genome biology platform. By leveraging large-scale gene knockout libraries, the company identifies potential therapeutic targets and advances them through preclinical and clinical development. Lexicon’s approach emphasizes the translation of genetic insights into targeted therapies for a range of human diseases.

The company’s most advanced product is telotristat ethyl (sold under the brand name XERMELO), an oral treatment approved for the management of carcinoid syndrome diarrhea in patients inadequately controlled by somatostatin analog therapy.